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Abstract
Background: Despite numerous interventions promulgated by the Surgical Care Improve Project (SCIP) and other
organizations, surgical site infection (SSI) continues to be a significant medical problem. DFA-02 is a novel
bioresorbable modified-release gel consisting of both gentamicin (16.8 mg/mL) and vancomycin (18.8 mg/mL)
to be applied during surgical incision closure for the prevention of SSIs. The following double-blind phase 2a
trial was designed to test the safety and tolerability of DFA-02.
Methods: At six US sites, the study planned to randomize 40 subjects undergoing colorectal surgery (30 with
DFA-02, and eight with placebo gel) in four ascending dose cohorts (10-, 20-, 30-, and 40-mL study drug per
wound). Safety was ascertained and serum pharmacokinetics (PK) was determined.
Results: Study enrollment was discontinued after the first three dose cohorts (10, 20, and 30 mL) as even very large
incisions could not accommodate more than 20 mL of gel, leaving no scientific justification for the 40-mL cohort.
DFA-02 was well tolerated and showed no evidence of local tissue reaction or impairment of wound healing. No
serious AEs were deemed related to study drug. Systemic exposure to gentamicin and vancomycin remained well
below levels considered to be at higher risk for oto- or nephrotoxicity. The maximal gentamicin and vancomycin
levels observed were 2.36 and 0.684 μg/mL at 6 h, which were well below the prespecified stopping criteria of 12
and 20 μg/mL, respectively.
Conclusions: In this small phase 2a study, the study drug was well tolerated and appeared to be free of serious
adverse effects. Consistent with these findings, the PK values were consistent with gradual release of the antibiotics
from the gel in the surgical site.
Trial registration: ClinicalTrials.gov, NCT01496352
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Background
Surgical site infections (SSIs) are a common nosocomial
infection in the USA and a significant cause of mortality
and morbidity (Leaper & Ousey 2015; Leaper et al.
2015). Strategies to reduce SSI have focused on many
factors, including, but not limited to, avoidance of shav-
ing (Ko et al. 1992), appropriate selection, timing and
dosing of prophylactic antibiotics (Bratzler et al. 2013),
and avoidance of hypothermia (Kurz et al. 1996). How-
ever, despite widespread implementation of these strat-
egies, SSIs remain common (Leaper & Ousey 2015),
although there is some evidence that implementation of
these bundles may be beginning to have a positive
impact (Tanner et al. 2015).
An attractive potential strategy involves administration
of a delayed release antibiotic into the surgical wound prior
to the completion of surgery. A gentamicin-containing
sponge has had mixed results; (Bennett-Guerrero et al.
2010; Bennett-Guerrero et al. 2010; Friberg et al. 2005;
Rutten & Nijhuis PH. Prevention of wound infection in
elective colorectal surgery by local application of a
gentamicin-containing collagen sponge. Eur J Surg Suppl
1997) efficacy was not observed in some trials, perhaps due
to the lack of a potent Gram-positive antimicrobial in the
product. DFA-02 is a novel bioresorbable modified-release
gel consisting of both gentamicin (16.8 mg/mL) and vanco-
mycin (18.8 mg/mL). This sterile, viscous, clear gel con-
tains sesame oil, soy lecithin, and dehydrated alcohol as
excipients. The doses selected for this study were based on
the antimicrobial activity, PK/pharmacodynamic (PD), and
toxicologic results of preclinical studies conducted with
prototype gentamicin/vancomycin gels and with DFA-02.
From the PK findings in multiple animal studies, it was
expected that the formulation of DFA-02, with
16.8 mg/mL gentamicin and 18.8 mg/mL vancomycin,
would provide local tissue levels greater than four
times the minimum inhibitory concentration (MIC) for
susceptible Gram-positive and Gram-negative pathogens
for up to 2 days after intraoperative application.
Therefore, the following phase 2a multicenter, random-
ized, double-blind, dose-ascending study was designed to
test the safety, tolerability, and pharmacokinetics of DFA-
02 in patients undergoing non-emergent colorectal
surgery.
Methods
This phase 2a study was sponsored/funded by Dr. Red-
dy’s Laboratories (Princeton, NJ) and coordinated by the
Duke Clinical Research Institute (DCRI, Durham, NC),
and was conducted at six US sites. It was registered at
clinicaltrials.gov (NCT01496352).
Ethics, consent, permissions, and competing inter-
ests—the study was approved by the Duke Health Sys-
tem Institutional Review Board as well as the IRBs
overseeing research at each of the sites as follows: The
Ohio State University Medical Center (Western Institu-
tional Review Board), Tampa General Hospital, and
University of South Florida South Tampa Center (Western
Institutional Review Board), Scott & White Healthcare
(Scott & White Healthcare Institutional Review Board),
Eliza Coffee Memorial Hospital (Western Institutional
Review Board), Memorial Hermann Memorial City
Medical Center (Western Institutional Review Board). All
subjects provided written informed consent. Safety was
reviewed on an ongoing basis by a colorectal surgeon
(Walter Koltun, MD, Hershey Medical Center, Hershey,
PA) not otherwise involved in the trial. This trial was
funded by the sponsor (Dr. Reddy’s Laboratories); how-
ever, the DCRI controlled the performance of all data
analysis and drafted the manuscript.
Adult patients undergoing colorectal surgery were
enrolled in this trial.
Inclusion criteria were as follows: (1) males and non-
pregnant females 18 years of age or older; (2) body mass
index (BMI) 25 to 40; and (3) scheduled to undergo
non-emergent colorectal surgery involving a laparotomy
incision of 7 cm or greater (hand-assisted laparoscopic
surgery was allowed). Eligible procedures included
left, right, or transverse colectomy; segmental/sleeve
left colon resection; total abdominal colectomy with
ileorectal anastomosis; total abdominal colectomy
with ileostomy; total abdominal proctocolectomy; low
anterior resection; sigmoid resection; non-emergent
Hartmann’s procedure; colotomy with polypectomy
distal to hepatic flexure; colostomy takedown through
laparotomy (not peristomal) incision; ileo-pouch anal
anastomosis; and abdominal perineal resection of the
rectum.
Exclusion criteria were as follows. (1) Known history
of hypersensitivity to gentamicin or vancomycin, other
aminoglycoside antibiotics, or the excipients of the study
products (soy bean products or sesame oil). (2) Emer-
gency surgery (urgent surgery was allowed if informed
consent was obtained and the study procedures could be
performed). (3) Significant concomitant surgical proced-
ure (note: concomitant appendectomy, cholecystectomy,
oophorectomy, and liver biopsy/wedge resection were
allowed). (4) Prior laparotomy within 60 days of this
planned procedure. (5) Planned second laparotomy or
colorectal surgical procedure (e.g., colostomy or ileos-
tomy takedown) within 30 days of this planned first
procedure. (6) Expectation that a surgical drain would
be placed. (7) Preoperative sepsis, severe sepsis, or septic
shock. (8) Abdominal wall infection/SSI from previous
laparotomy/laparoscopy or for any reason. (9) Active
systemic infection or systemic (oral or intravenous) anti-
biotic therapy within 1 week before the date of surgery
other than specified preoperative antimicrobial
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prophylaxis (note: single-dose antibiotic therapy for den-
tal or other minor procedures was allowed as was the
use of oral nonabsorbable antibiotics for preoperative
bowel decontamination). (10) Requirement for gentami-
cin or vancomycin preoperative antimicrobial prophy-
laxis (note: systemic antibiotic therapy within 72 h after
surgery with gentamicin or vancomycin was to be
avoided, and any systemic antibiotic therapy during that
time was to be discussed with the Coordinating Center
Principal Investigator or Medical Monitor). (11) Require-
ment for concomitant use or use during the 30 days be-
fore day 1 of any prescription or over-the-counter drug
that would interfere with the study or place the patient
at undue risk. Concurrent systemic or topical use of
other potentially neurotoxic, nephrotoxic, and/or oto-
toxic drugs, such as gentamicin, cisplatin, cephaloridine,
kanamycin, amikacin, polymyxin B, colistin, paromomy-
cin, streptomycin, tobramycin, vancomycin, ethacrynic
acid, furosemide, and viomycin, was to be avoided. (12)
Preoperative evaluation suggested an intra-abdominal
process that might preclude full closure of the skin. (13)
Ongoing treatment (e.g., chemotherapy, radiation) for
non-colorectal cancer. (14) History of significant drug or
alcohol abuse within the past year. (15) Serum creatinine
>1.3 mg/dL. (16) Serum bilirubin >2.5 times upper limit
of normal. (17) History of uncontrolled diabetes mellitus
(controlled diabetic patients whose hemoglobin A1c was
≤9.0 % could be included). (18) Patients who were im-
munocompromised, including, but not limited to, sys-
temic corticosteroid use or chemotherapy/radiation
during the 30 days before surgery, organ transplantation,
or human immunodeficiency virus infection (note: inhaled
corticosteroids were not exclusionary, and single-dose use
of corticosteroids to prevent postoperative nausea and
vomiting was allowed). (19) Any clinically meaningful
hearing loss (from medical history). (20) Clinically exclu-
sionary results on clinical laboratory, electrocardiogram,
or physical examination, including, but not limited to,
positive hepatitis B or C or human immunodeficiency
virus. (21) Pregnant or lactating or if of childbearing
potential and not practicing a birth control method with a
high degree of reliability. (22) Refusal to accept medically
indicated blood products. (23) Participation within 30 days
before the start of this study in any experimental drug or
device study or currently participating in a study in which
the administration of investigational drug or device within
60 days was anticipated. (24) Patients with anterior ab-
dominal wall mesh that was not planned to be completely
removed during the planned procedure. (25) Unable
to participate in the study for any reason in the opin-
ion of the PI. (26) Postsurgical life expectancy of less
than 30 days, in the investigator’s or sponsor’s opin-
ion. (27) Expected discharge from the hospital less
than 3 days after surgery.
Study drug
DFA-02 is a novel bioresorbable modified-release gel
consisting of both gentamicin (16.8 mg/mL) and vanco-
mycin (18.8 mg/mL). This sterile, viscous, clear gel con-
tains sesame oil, soy lecithin, and dehydrated alcohol as
excipients. The placebo gel was exactly the same as
DFA-02 except for the active ingredients. The products
were manufactured by NextPharma, Inc. (San Diego,
CA). DFA-02 and matching placebo were supplied as
10 mL in 20-mL glass vials. The product was stored
at −25 to −10 °C. It was thawed at room temperature
until clear and used within 7 days of thawing. It was
not refrozen and reused.
Randomization and study drug administration
Patients were randomized using a computer generated
randomization scheme prepared by the trial’s statistician
at the DCRI. DFA DFA-02 10, 20, or 30 mL or matching
placebo was administered once at the conclusion of sur-
gery in the operating room. The gel from one or two
vials (10 or 20 mL) was drawn into a 30-mL syringe
(provided by the sponsor) from the vial with a 14-gauge
needle (also provided by the sponsor) or, alternatively,
the gel from the vial could be decanted into a sterile
container/cup and drawn into the syringe without a
needle. For the 10- and 20-mL cohorts, a single 30-mL
syringe was used, and for the 30-mL cohort, two 30-mL
syringes were used. After closure of the fascia, the gel
was administered from the syringe, evenly covering the
subcutaneous tissue of the index incision (the longest
incision if more than one incision was made). The sub-
cutaneous tissue was then approximated and the incision
closed with either sutures or staples. Any extruded gel
after closure was collected in a syringe, the volume
recorded by the surgeon, and then discarded. Only the
longest (index) laparotomy incision was treated with
study drug. If a patient required reopening of the surgi-
cal incision for any reason, no additional study drug was
applied.
Prohibited and concomitant medications/procedures
Consistent with the Surgical Care Improve Project
(SCIP) guidelines, all patients received standard pre-
operative antimicrobial prophylaxis antibiotics within
60 min of initial skin incision. Antibiotic prophylaxis
was not continued for more than 24 h. Antibiotic
prophylaxis could be redosed during surgery for long
procedures based on SCIP guidelines. The use of oral
nonabsorbable preoperative antibiotic treatment was
at the discretion of the surgeon. Adherence to other
SCIP guidelines, e.g., maintenance of normothermia,
method of hair removal, was recorded. Prohibited
interventions included administration of topical anti-
microbials (e.g., Betadine), systemic gentamicin or
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vancomycin preoperatively or within 72 h of surgery,
and prophylactic use of negative pressure dressings
(e.g., WoundVac, StripVac).
Outcomes/recorded variables
The main objectives of the study were to (1) evaluate the
safety and tolerability of ascending doses of DFA-02 in
patients undergoing colorectal surgery and (2) evaluate
the systemic PK of gentamicin and vancomycin after
single doses of 10 to 40 mL of DFA-02 in patients
undergoing colorectal surgery.
Safety and tolerability were assessed by (1) physical
examination; (2) surgical incision examination on days 2,
3, and 5 (24, 48, and 96 h postoperatively) and day 14;
(3) vital signs: screening (baseline), day of surgery (pre-
and postoperatively), days 2, 3, 5, and 14; (4) clinical
laboratory tests (hematology, clinical chemistry, urinaly-
sis): screening, days 5 and 14; (5) ECG: screening (base-
line), day 5; (6) adverse event recording on days 1, 2, 3,
5, 14, and 30; (7) ASEPSIS score on day 5 (96 h) postop-
eratively; and (8) wound questionnaire on day 30.
Additional recorded variables included (1) evaluation
of postoperative renal function as manifested by serum
creatinine levels on days 5 and 14 compared with base-
line and (2) evaluation of the incidence of antibiotic
resistance based on baseline and postoperative rectal/
stool and nasal culture and sensitivities for vancomycin-
resistant enterococcus (VRE) and MRSA, respectively,
and antibiotic sensitivity of any culture positive SSIs.
Molecular typing was also utilized to identify MRSA and
VRE in lieu of culture and sensitivity.
Systemic PK of gentamicin and vancomycin were
determined from serial blood draws obtained at 1, 6,
24, 48, and 96 h after study drug administration.
These assays were performed at MicroConstants, Inc
(San Diego, CA).
Statistical methods
The sample size and study design were typical for phase
2 safety, tolerability, and PK studies, and the study was
not statistically powered. This study planned to enroll 40
patients (ten per cohort) undergoing colorectal surgery
with a planned incision of 7 cm or greater. Four dose co-
horts were planned: 10, 20, 30, and 40 mL of DFA-02
administered as a single dose into the surgical incision
at closure. All study data were summarized using de-
scriptive statistics at each assessment time for each treat-
ment group based on actual values and change from
baseline/screening values. Continuous variables were
summarized using n, mean, standard deviation (SD), and
minimum, median, and maximum values. Categorical
variables were summarized using the number and per-
centage of patients in each category. Gentamicin and
vancomycin plasma levels were obtained 1 and 6 h after
study drug application and on days 2, 3, and 5 (24, 48
and 96 h after application). Cmax, AUC0–t, AUC0–∞, Tmax,
t1/2, CL/F, and V/F were calculated from the plasma con-
centrations using standard methods.
Results
Study enrollment was discontinued after the first three
dose cohorts (10, 20, and 30 mL) as even very large inci-
sions could not accommodate more than 20 mL of gel,
leaving no scientific justification for the 40 mL cohort.
Each cohort contained ten subjects (two patients receiv-
ing placebo and eight patients receiving study drug). It
was anticipated that not all of the study drug would be
retained in the wound, e.g., smaller incisions, so we re-
corded the net volume of study drug retained. Therefore,
results (Table 1) are presented for subjects with ≤10 mL
vs >10 mL retained study drug.
Table 1 shows preoperative and intraoperative vari-
ables. The study dose groups showed some differences
in distributions of baseline and intraoperative character-
istics consistent with the relatively small sample size
inherent to the phase 2 design.
DFA-02 was well tolerated and showed no evidence
of local tissue reaction or impairment of wound heal-
ing. The majority of treatment-emergent adverse
events (TEAEs) were those commonly seen with colo-
rectal surgery. No serious AEs were considered to be
related to study drug. Serum creatinine measured on
postoperative days 4 (or discharge) and 14 were not
significantly increased compared with baseline values.
No patients showed MRSA in preoperative nasal
cultures or VRE in preoperative rectal cultures. One
patient in the DFA-02 group showed nasal MRSA
and one patient in the placebo group showed rectal
VRE at discharge.
Systemic exposure to gentamicin and vancomycin
remained well below levels considered to be at higher
risk for oto- or nephrotoxicity. The maximal gentamicin
level for any patient was 2.36 μg/mL at 6 h, which was
well below the prespecified stopping criterion of
12 μg/mL at 6 h. The maximal vancomycin level for
any patient was 0.684 μg/mL at 6 h, well below the
prespecified stopping criterion of 20 μg/mL. Pharma-
cokinetic data are shown in Table 2 and Figs. 1 and
2. The PK analysis showed that following single
administration of DFA-02 gel at 10, 20, or 30 mL
(nominal volume) to surgical wounds, gentamicin was
absorbed into the systemic circulation with median
Tmax values of 6.00, 6.09, 6.15, and 6.01 h for cohorts
1, 2, 3, and all cohorts combined, respectively. The
Tmax values appeared to be dose-independent. The
mean Cmax values were 0.693, 0.626, 0.608, and
0.642 μg/mL for cohorts 1, 2, 3, and all cohorts com-
bined, respectively. Corresponding mean AUC0–t
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values were 15.30, 15.20, 12.10, and 14.20 μg∙h/mL
for cohorts 1, 2, 3, and all cohorts combined, respect-
ively. Vancomycin was absorbed into the systemic
circulation with median Tmax values of 6.57, 23.9,
24.1, and 22.2 h for cohorts 1, 2, 3, and all cohorts
combined, respectively. The median Tmax in cohorts 2
and 3 was longer than that of cohort 1. The mean Cmax
values were 0.157, 0.168, 0.166, and 0.164 μg/mL for
cohorts 1, 2, 3, and all cohorts combined, respectively.
Corresponding mean AUC0–t values were 6.41, 6.28, 6.71,
and 6.47 μg h/mL in cohorts 1, 2, 3, and all cohorts com-
bined, respectively.
The study was not designed or powered to rigorously
assess SSIs; however, no significant differences were
observed in this endpoint (placebo 1/6 = 16.7 %, DFA-
02 ≤10 mL retained dose 3/16 = 18.8 %, DFA-02 >10 mL
retained dose 2/8 = 25 % SSI rate).
Discussion
This phase 2 dose-ascending tolerability, safety, and
pharmacokinetic study met its objectives. The inclusion
of a placebo group in each dosing cohort enabled us to
maintain a double-blind study, avoiding possible bias
with regard to assessments of safety and tolerability.
Consistent with preclinical animal studies conducted by
the sponsor, DFA-02 was well tolerated and showed no
evidence of local tissue reaction or impairment of wound
healing. Safety was assessed by collection of adverse
events and by recording safety events of interest, e.g.,
related to renal function and serum levels of the antibi-
otics. No serious adverse events were deemed related to
study drug.
Postoperative renal function, assessed by mean serum
creatinine levels, showed no adverse effect for DFA-02
compared with placebo gel. A single patient had a
Table 1 Patient and procedure characteristics and study drug administration
Characteristic Placebo DFA-02 ≤10 mL DFA-02 >10 mL
(n = 6) (n = 16) (n = 8)
Age, years 56.5 (45.1,60.6) 70.9 (63.2, 76.3) 46.9 (41.4, 61.2)
Gender, % male 2 (33.3 %) 6 (37.5 %) 4 (50 %)
Race, % white 5 (83.3 %) 14 (87.5 %) 7 (87.5 %)
Weight, kg 74.7 (72.3,76.4) 90.9 (72.3,97.1) 81.8 (73.3, 97.5)
Height, cm 164.3 (157.5, 175.2) 167.6 (158.7, 175.3) 171.4 (165.1, 180.4)
Body mass index (kg/m2) 28.2 (27.0, 29.9) 29.1 (27.8, 33.9) 28.2 (25.7, 30.6)
Preoperative serum creatinine (mg/dL) 0.7 (0.7, 0.9) 0.9 (0.8, 1.3) 0.9 (0.8, 1.0)
Duration of surgical procedure (h) 2.8 (1.4, 4.6) 2.0 (1.1, 2.3) 3.0 (2.4, 5.6)
Length of incision (cm) 11.3 (8.0, 26.0) 8.2 (7.8, 10.0) 8.5 (7.8, 10.5)
Depth of incision at midpoint (cm) 2.2 (1.5, 3.0) 2.5 (1.5, 3.3) 2.5 (2.0, 3.0)
Wound area (cm2) 45.7 (11.1, 79.7) 22.3 (12.1, 30.0) 22.8 (18.0, 32.3)
Study drug volume inserted into wound (mL) 19.0 (10.0, 20.0) 10.0 (10.0, 20.0) 25.0 (20.0, 30.0)
Overflow study drug collected (mL) 4.5 (3.0, 7.0) 5.0 (1.5, 12.5) 12.0 (6.0, 15.0)
Volume of study drug retained in wound (mL) 9.5 (5.0, 17.0) 5.0 (4.5, 9.8) 15.0 (12.5, 15.5)
Volume of study drug per wound area (mL/cm2) 0.2 (0.2, 0.5) 0.3 (0.2, 0.4) 0.6 (0.5, 0.7)
As appropriate data shown as percentage or median (25th, 75th percentiles)
Table 2 Summary of gentamicin and vancomycin pharmacokinetic parameters in all cohorts
Characteristic Actual dosea Tmax Cmax AUC(0–t) t1/2
(mg) (h) (mcg/mL) (mcg h/mL) (h)
Gentamicin
n 24 24 24 24 18
Mean (SD) 149 (75.9) 6.01 (3.48) 0.642 (0.524) 14.2 (12.6) 17.7 (4.98)
Vancomycin
n= 24 21 24 24 0
Mean (SD) 167 (84.9) 22.2 (18.7) 0.164 (0.150) 6.47 (8.12) NC
AUC area under the curve, Cmax, maximum concentration, h hour, mcg microgram, mg milligram, mL milliliter, N number, NC not calculated, SD standard deviation,
t½ half-life
aMean amount of drug retained for all cohorts 8.9 ± 4.52 mL
Bennett-Guerrero et al. Perioperative Medicine  (2016) 5:17 Page 5 of 8
creatinine elevation 2 days after surgery that returned
to normal within 3 days. The maximum recom-
mended daily intravenous dose for gentamicin in pa-
tients with normal renal function is 1.7 mg/kg every
8 h or 306 mg/day for a 60-kg patient with a goal of
avoiding peak systemic levels greater than 12 μg/mL
and trough levels greater than 2 μg/mL (Gentamicin
Dosage - Drugs.com. Available at: http://www.drugs.co
m/dosage/gentamicin.html#Usual_Adult_Dose_for_Sur
gical_Prophylaxis. Accessed July 2 2013). The usual
recommended IV dose for vancomycin is 2 g/day with
a therapeutic goal of 15 to 20 μg/L (Vancomycin
Dosage - Drugs.com. Available at: http://www.drugs.
com/dosage/vancomycin.html. Accessed July 2 2013).
In both rabbit and pig models of wound healing, sys-
temic concentrations of gentamicin have been below
the systemic peak level, 12 μg/mL, above which nephro-
and ototoxicity are more likely to occur, and vancomycin
concentrations have been below 20 μg/mL. The highest
maximum concentration (Cmax)/DFA-02 dose correlations
observed in preclinical in vivo studies were 0.69 μg/mL
for gentamicin and 0.33 μg/mL for vancomycin, observed
in a pig model of wound healing (Study MPI 1115-019,
Dr. Reddy’s Laboratories). Extrapolating from the Cmax/
dose correlations in pigs, the expected human Cmax for a
60-kg person receiving 40 mL of DFA-02 was estimated to
be 7.8 μg/mL for gentamicin and 4.2 μg/mL for vanco-
mycin, both within the clinically accepted range. In our
study, the maximal levels of gentamicin and vancomycin
for any patient were 2.36 and 0.684 μg/mL at 6 h, respect-
ively, well below the prespecified stopping criteria for the
study. In fact, the maximum dose actually tested was
Dose, mg






























Fig. 1 a and b show the Cmax and AUC0–t of gentamicin following a single administration of DFA-02 (actual dose)
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30 mL since as even very large incisions could not accom-
modate more than 20 mL of gel, leaving no scientific justi-
fication for advancing dose escalation to the 40 mL
cohort. The systemic PK suggested slow release of the
antibiotics from the gel in the incision site.
Our study has several limitations. As is typical for
most “first in patient” studies, in order to optimize safety
of study subjects, there was an extensive list of exclusion
criteria, which can limit the generalizability of these re-
sults to all surgical patients. In particular, while preclin-
ical models showed no adverse effects of the study drug
on renal function, to be conservative, we excluded
patients with serum creatinine >1.3 mg/dL preopera-
tively. While no adverse effect was shown on renal
function, we cannot rule out different results in pa-
tients with preexisting renal dysfunction. As expected,
and consistent with the small sample size, we observed
imbalances between study arms in several patient charac-
teristics. It is important to note, however, that this should
not affect many of the study’s findings given the nature of
the pharmacokinetic and other analyses. Finally, our study
was not powered to draw any conclusions as to the effi-
cacy of DFA-02 in preventing SSIs in colorectal surgery. A
larger multicenter study is designed to evaluate the effi-
cacy of DFA-02 with respect to prevention of SSI.
Conclusions
In this small phase 2a study, the study drug was well
tolerated and appeared to be free of serious adverse
effects. Consistent with these findings, the PK values
were consistent with gradual release of the antibiotics
from the gel in the surgical site.
Dose, mg



































Fig. 2 a and b show the Cmax and AUC0–t of vancomycin following a single administration of DFA-02 (actual dose)
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